-+ 0.00%
-+ 0.00%
-+ 0.00%

Ipsen H1 FY26 core operating income climbs 28.8% to €844.9 million; sales rise 20.4% to €2.19 billion

PUBT·07/30/2026 05:05:51
Listen to the news
Ipsen H1 FY26 core operating income climbs 28.8% to €844.9 million; sales rise 20.4% to €2.19 billion
  • Ipsen posted H1 2026 total sales of €2.19 billion, up 20.4% from a year earlier.
  • Core operating income climbed 28.8% to €844.9 million, lifting the core operating margin by 2.5 percentage points to 38.6%.
  • IFRS operating income rose 25.1% to €564.8 million, while IFRS net profit increased 20% to €402.6 million.
  • CEO David Loew cited broad-based momentum across all three therapeutic areas, with the portfolio beyond Somatuline accelerating.
  • Upgraded FY 2026 outlook: total sales growth above 20% at constant currency, core operating margin above 37% of total sales.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ipsen SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300100PRIMZONEFULLFEED1001255083) on July 30, 2026, and is solely responsible for the information contained therein.